Nicholas P. Kwiatkowski
Affiliations: | 2012 | Harvard University, Cambridge, MA, United States |
Google:
"Nicholas Kwiatkowski"Mean distance: 7.38 | S | N | B | C | P |
Parents
Sign in to add mentor| Christopher T. Walsh | grad student | 2012 | Harvard | |
| (Development of Mps1, Aurora and Cdk7 inhibitors and their application to the analysis of the cell cycle.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Gao Y, Jiang B, Kim H, et al. (2023) Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions. Journal of Medicinal Chemistry |
| Lu W, Fan M, Ji W, et al. (2023) Structure-Based Design of Y-Shaped Covalent TEAD Inhibitors. Journal of Medicinal Chemistry |
| Bohmer MJ, Wang J, Istvan ES, et al. (2023) Human Polo-like Kinase Inhibitors as Antiplasmodials. Acs Infectious Diseases |
| Yao Y, Fong Ng J, Park WD, et al. (2023) CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma. Blood |
| Fan M, Lu W, Che J, et al. (2022) Covalent disruptor of YAP-TEAD association suppresses defective hippo signaling. Elife. 11 |
| Gao Y, Volegova M, Nasholm N, et al. (2022) Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma. Frontiers in Oncology. 11: 773186 |
| Son J, Jang J, Beyett TS, et al. (2022) A novel HER2-selective kinase inhibitor is effective in HER2 mutant and amplified non-small cell lung cancer. Cancer Research |
| Ryu S, Park JE, Ham YJ, et al. (2022) Novel Macrocyclic Peptidomimetics Targeting the Polo-Box Domain of Polo-Like Kinase 1. Journal of Medicinal Chemistry |
| Vervoort SJ, Devlin JR, Kwiatkowski N, et al. (2021) Targeting transcription cycles in cancer. Nature Reviews. Cancer. 22: 5-24 |
| Jiang B, Jiang J, Kaltheuner IH, et al. (2021) Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma. European Journal of Medicinal Chemistry. 221: 113481 |